Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer

Molecular Therapy

Volumn 16, Issue 12, 2008, Pages 1910-1918

  Kottke, Timothy ^a   Diaz, Rosa M ^a   Kaluza, Karen ^a,b   Pulido, Jose ^a   Galivo, Feorillo ^a   Wongthida, Phonphimon ^a   Thompson, Jill ^a   Willmon, Candice ^a   Barber, Glen N ^c   Chester, John ^d   Selby, Peter ^d   Strome, Scott ^e   Harrington, Kevin ^f   Melcher, Alan ^d   Vile, Richard G ^a,b,d  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOCOMPETENCE; IN VIVO STUDY; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VESICULAR STOMATITIS VIRUS;

ADAPTATION, BIOLOGICAL; ANIMALS; ANTIBODIES; ANTIGENS; CELL LINE, TUMOR; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; MICE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; T-LYMPHOCYTES; VESICULOVIRUS;

MUS; VESICULAR STOMATITIS VIRUS;

EID: 56749164906     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.212     Document Type: Article

References (49)

1. Fisher, K (2006). Striking out at disseminated metastases: The systemic delivery of oncolytic viruses. Curr Opin Mol Ther 8: 301-313.
2. Bell, JC (2007). Oncolytic viruses: What's next? Curr Cancer Drug Targets 7: 127-131.
3. Harrington, K, Alvarez-Vallina, L, Crittenden, M, Gough, M, Chong, H, Diaz, RM et al. (2002). Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther 13: 1263-1280.
4. Power, AT, Wang, J, Falls, TJ, Paterson, JM, Parato, KA, Lichty, BD et al. (2007). Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 15: 123-130.
5. Ikeda, K, Wakimoto, H, Ichikawa, T, Jhung, S, Hochberg, FH, Louis, DN et al. (2000). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 74: 4765-4775.
6. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878.
7. Friedman, A, Tian, JP, Fulci, G, Chiocca, EA and Wang, J (2006). Glioma virotherapy: Effects of innate immune suppression and increased viral replication capacity. Cancer Res 66: 2314-2319.
8. Qiao, J, Wang, X, Kottke, T, White, C, Twigger, K, Diaz, RM et al. (2008). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of Reovirus. Clin Cancer Res 14: 259-269.
9. Cole, C, Qiao, J, Kottke, T, Diaz, RM, Ahmed, A, Sanchez-Perez, L et al. (2005). Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 11: 1073-1081.
10. Thanarajasingam, U, Sanz, L, Diaz, RM, Qiao, J, Sanchez-Perez, L, Kottke, T et al. (2007). Delivery of CCL-21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res 67 300-308.
11. Yotnda, P, Savoldo, B, Charlet-Berguerand, N, Rooney, C and Brenner, M (2004). Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood 104: 2272-2280.
12. Thorne, SH, Negrin, RS and Contag, CH (2006). Synergistic antitumor effects of immune cell-viral biotherapy. Science 311: 1780-1784.
13. Ong, HT, Hasegawa, K, Dietz, AB, Russell, SJ and Peng, KW (2007). Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 14: 324-333.
14. Gomez-Navarro, J, Contreras, JL, Arafat, W, Jiang, XL, Krisky, D, Oligino, T et al. (2000). Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther 7: 43-52.
15. Dudley, ME and Rosenberg, SA (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3: 666-676.
16. Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
17. Gattinoni, L, Powell, DJ Jr, Rosenberg, SA and Restifo, NP (2006). Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 6: 383-393.
18. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
19. Yee, C, Thompson, JA, Byrd, D, Riddell, SR, Roche, P, Celis, E et al. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173.
20. Kottke, T, Qiao, J, Diaz, RM, Ahmed, A, Vroman, B, Thompson, J et al. (2006). The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles. Gene Ther 13: 1166-1177.
21. Harrington, K and Vile, R (2006). Virus smuggling, tax evasion and tumor assassination. Nat Med 12: 507-509.
22. Hogquist, KA, Jameson, SC, Health, WR, Howard, JL, Bevan, MJ and Carbone, FR (1994). T cell receptor antagonistic peptides induce positive selection. Cell 76: 17.
23. Kelly, E and Russell, SJ (2007). History of oncolytic viruses: Genesis to genetic engineering. Mol Ther 15: 651-659.
24. Kirn, D, Martuza, RL and Zwiebel, J (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787.
25. Lichty, BD, Power, AT, Stojdl, DF and Bell, JC (2004). Vesicular stomatitis virus: Reinventing the bullet. Trends Mol Med 10: 210-216.
26. Barber, GN (2004). Review: Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 17: 516-527.
27. Barber, GN (2005). VSV tumor selective replication and protein translation. Oncogene 24: 7710-7719.
28. Fernandez, M, Porosnicu, M, Markovic, D and Barber, GN (2002). Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 76: 895-904.
29. Ebert, O, Harbaran, S, Shinozaki, K and Woo, SL (2005). Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther 12: 350-358.
30. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6 821-825.
31. Qiao, J, Wang, H, Kottke, T, Diaz, RM, Willmon, C, Hudacek, A et al. (2008). Loading of oncolytic vesicular stomatitis virus onto antigen specific T cells enhances the efficacy of adoptive T cell therapy of tumors. Gene Ther 15: 604-616.
32. Qiao, J, Kottke, T, Willmon, C, Galivo, F, Wongthida, P, Diaz, RM et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
33. Muranski, P, Boni, A, Wreszinski, C, Citrin, DE, Rosenberg, SA, Childs, R et al. (2006). Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go? Nat Clin Pract Oncol 3: 668-681.
34. Baluna, R and Vitetta, ES (1997). Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology 37: 117-132.
35. Rosenberg, SA, Mule, JJ, Spiess, PJ, Reichert, CM and Schwarz, SL (1985). Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169-1188.
36. Nakajima, T, Schulte, S, Warrington, KJ, Kopecky, SL, Frye, RL, Goronzy, JJ et al. (2002). T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 105: 570-575.
37. Yoneda, O, Imai, T, Goda, S, Inoue, H, Yamauchi, A, Okazaki, T et al. (2000). Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 164: 4055-4062.
38. Melencio, L, McKallip, RJ, Guan, H, Ramakrishnan, R, Jain, R, Nagarkatti, PS et al. (2006). Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak. Int Immunol 18: 1461-1471.
39. Renkonen, R, Ristimaki, A and Havry, P (1998). Interferon-γ protects human endothelial cells from lymphokine-activated killer cell-mediated lysis. Eur J Immunol 18: 1839-1842.
40. Kottke, T, Galivo, F, Wongthida, P, Diaz, RM, Thompson, J, Jevremovic, D et al. (2008). Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors by systemically delivered oncolytic virus. Mol Ther 16: 1217-1226.
41. Sanchez-Perez, L, Gough, M, Qiao, J, Thanarajasingam, U, Kottke, T, Ahmed, A et al. (2007). Synergy of adoptive T-cell therapy with intratumoral suicide gene therapy is mediated by host NK cells. Gene Ther 14: 998-1009.
42. Diaz, RM, Galivo, F, Kottke, T, Wongthida, P, Qiao, J, Thompson, J et al. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848.
43. Di Paolo, NC, Tuve, S, Ni, S, Hellstrom, KE, Hellstrom, IE and Lieber, A (2006). Effects of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res 66: 960-969.
44. Klebanoff, CA, Finkelstein, SE, Surman, DR, Lichtman, MK, Gattinoni, L, Theoret, MR et al. (2004). IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101: 1969-1974.
45. Muranski, P, Boni, A, Antony, PA, Cassard, L, Irvine, KR, Kaiser, A et al. (2008). Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
46. Linardakis, E, Bateman, A, Phan, V, Ahmed, A, Gough, M, Olivier, K et al. (2002). Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 62: 5495-5504.
47. Daniels, G, Sanchez-Perez, L, Kottke, T, Diaz, RM, Thompson, J, Lai, M et al. (2004). A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 22: 1125-1132.
48. Coligan, JE, Kruisbeek, AM, Margulies, DH, Shevach, EM and Strober, W (1998). Current Protocols in Immunology. Wiley: New York.
49. Altman, DG (1991). Analysis of survival times. Practical Statistics for Medical Research.Chapman Hall: London, pp. 365-395.